Merck Sharp + Dohme Corp.

Sarah L Trice

John S Wai

Peter D Williams

Shankar Venkatraman

Wayne J Thompson

Dai-Shi Su

Mark W Embrey

Peter Emmanuel Maligres

Zhiguo Jake Song

Thorsten E Fisher

Tao Pei

Jingjun Yin

David C Dubost

Michael Shevlin

Richard C A Isaacs

Neil A Strotman

Richard G Ball

Matthew L Maddess

Dietrich P Steinhuebel

Eric J Choi

Neil Campbell

Matthew Maddess

Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X, X, Y, R, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.

HIV integrase inhibitors

Growing community of inventors

Glenside, PA, United States of America

Sarah L Trice